Promising preclinical and clinical data have demonstrated high potency of BTK inhibitor Ibrutinib for the treatment of various B cell malignancies, such as MCL, CLL and ABC DLBCL [6]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.